Trial Profile
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Cytarabine; Fludarabine; Idarubicin
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 17 Apr 2018 Planned End Date changed from 1 Feb 2018 to 15 Dec 2017.
- 17 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 15 Dec 2017.
- 17 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment.